Cidara Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Cidara Therapeutics, Inc. carries a market capitalization of 5.61B, placing it among publicly traded companies globally. Its enterprise value stands at 1.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.61B |
| Enterprise Value | 1.17B |
Share Statistics
Cidara Therapeutics, Inc. currently has 29.34M shares outstanding.
| Shares Outstanding | 29.34M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -2.14 |
| P/TBV Ratio | 3.76 |
| P/FCF Ratio | -11.95 |
| P/OCF Ratio | -11.95 |
Financial Position
Cidara Therapeutics, Inc. maintains a current ratio of 4.62, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.62 |
| Quick Ratio | 4.40 |
| Debt / Equity | 0.47 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -54.26 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.51 |
Stock Price Statistics
Cidara Therapeutics, Inc.'s stock has gained approximately 921.12546% over the past 52 weeks. The 50-day moving average sits at 187.66, while the 200-day moving average is 84.67.
| Beta (5Y) | N/A |
| 52-Week Price Change | 921.12546% |
| 50-Day Moving Average | 187.66 |
| 200-Day Moving Average | 84.67 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -195.30M, while operating income came in at -195.46M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -195.46M |
| Pretax Income | -184.80M |
| Net Income | -184.74M |
| EBITDA | -195.30M |
| EBIT | -195.46M |
| Earnings Per Share (EPS) | -11.14 |
Balance Sheet
Cidara Therapeutics, Inc. holds 420.02M in cash and equivalents against 1.98M in total debt, resulting in a net debt position of -293.65M. Total book value stands at -743.69M, with working capital of 346.98M providing operational flexibility.
| Cash & Cash Equivalents | 420.02M |
| Total Debt | 1.98M |
| Net Debt | -293.65M |
| Equity (Book Value) | -743.69M |
| Book Value Per Share | -44.84 |
| Working Capital | 346.98M |
Cash Flow
Cidara Therapeutics, Inc. produced -132.94M in operating cash flow over the past twelve months.
| Operating Cash Flow | -132.94M |
| Capital Expenditures | N/A |
| Free Cash Flow | -132.94M |
| FCF Per Share | -8.02 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -30.34 |
| FCF Yield | -8.37 |
Stock Splits
Cidara Therapeutics, Inc.'s most recent stock split took place on April 24, 2024 with a 20:1 split ratio.
| Last Split Date | 4/24/2024 |
| Split Ratio | 20:1 |
Scores
Cidara Therapeutics, Inc. posts an Altman Z-Score of 7.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.45 |